Why the study?
Does an inactivated rhinovirus type 13 vaccine administered intranasally prevent illness after viral challenge in adult male volunteers?
Population
Adult male volunteers (n=30 total: 17 vaccinees, 13 seronegative controls)
Comparison
Inactivated rhinovirus type 13 vaccine… vs Seronegative controls
Design
Other
Authors
Loading...
May reduce illness after controlled rhinovirus challenge in adult males; leaves open real-world efficacy and need for larger trials.
Does an inactivated rhinovirus type 13 vaccine administered intranasally prevent illness after viral challenge in adult male volunteers?
Intranasal administration of an inactivated rhinovirus type 13 vaccine significantly reduces the incidence of illness following viral challenge in adult males.
Perkins et al. (1969) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: